Cargando…
Topical application of an amygdalin analogue reduces inflammation and keratinocyte proliferation in a psoriasis mouse model
Psoriasis is a chronic inflammatory skin disease without cure. Systemic and biological therapies are the most effective treatments for patients with severe psoriasis. However, these drugs can cause serious side effects from extended use. Safe and effective topical drugs are needed to decrease psoria...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8597152/ https://www.ncbi.nlm.nih.gov/pubmed/33998705 http://dx.doi.org/10.1111/exd.14390 |
_version_ | 1784600551661502464 |
---|---|
author | Gago‐López, Nuria Lagunas Arnal, Carmen Perez, Juan J. Wagner, Erwin F. |
author_facet | Gago‐López, Nuria Lagunas Arnal, Carmen Perez, Juan J. Wagner, Erwin F. |
author_sort | Gago‐López, Nuria |
collection | PubMed |
description | Psoriasis is a chronic inflammatory skin disease without cure. Systemic and biological therapies are the most effective treatments for patients with severe psoriasis. However, these drugs can cause serious side effects from extended use. Safe and effective topical drugs are needed to decrease psoriatic plaques and reduce the risk of adverse effects. Amygdalin analogues are stable small molecules that showed benefits in psoriasis xenografts to immune‐deficient mice by systemic application. However, whether topical application of these amygdalin analogues could reduce the progression of the psoriatic phenotype in an immune‐competent organism is unknown. Here, we analyse the efficiency of topical application of an amygdalin analogue cream on a well‐established genetic and immune‐competent mouse model of psoriasis. Topical application of an amygdalin analogue cream ameliorates psoriasis‐like disease in mice, reduces epidermal hyperplasia and skin inflammation. Amygdalin analogue treatment leads to reduced expression of local pro‐inflammatory cytokines, but systemic pro‐inflammatory cytokines that are highly expressed in psoriasis patients such as IL‐17A, IL6 or G‐CSF are also decreased. Furthermore, expression of important mediators of psoriasis initiation and epidermal hyperplasia, such as TNFa, S100A9 and TSLP, is decreased in lesional epidermis after amygdalin analogue treatment. In conclusion, we show that amygdalin analogue reduces the proliferative capacity of psoriasis‐like stimulated keratinocytes and their inflammatory response in vivo and in vitro. These results suggest that topical application of amygdalin analogues may represent a safe and effective treatment for psoriasis. |
format | Online Article Text |
id | pubmed-8597152 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-85971522021-11-22 Topical application of an amygdalin analogue reduces inflammation and keratinocyte proliferation in a psoriasis mouse model Gago‐López, Nuria Lagunas Arnal, Carmen Perez, Juan J. Wagner, Erwin F. Exp Dermatol Regular Articles Psoriasis is a chronic inflammatory skin disease without cure. Systemic and biological therapies are the most effective treatments for patients with severe psoriasis. However, these drugs can cause serious side effects from extended use. Safe and effective topical drugs are needed to decrease psoriatic plaques and reduce the risk of adverse effects. Amygdalin analogues are stable small molecules that showed benefits in psoriasis xenografts to immune‐deficient mice by systemic application. However, whether topical application of these amygdalin analogues could reduce the progression of the psoriatic phenotype in an immune‐competent organism is unknown. Here, we analyse the efficiency of topical application of an amygdalin analogue cream on a well‐established genetic and immune‐competent mouse model of psoriasis. Topical application of an amygdalin analogue cream ameliorates psoriasis‐like disease in mice, reduces epidermal hyperplasia and skin inflammation. Amygdalin analogue treatment leads to reduced expression of local pro‐inflammatory cytokines, but systemic pro‐inflammatory cytokines that are highly expressed in psoriasis patients such as IL‐17A, IL6 or G‐CSF are also decreased. Furthermore, expression of important mediators of psoriasis initiation and epidermal hyperplasia, such as TNFa, S100A9 and TSLP, is decreased in lesional epidermis after amygdalin analogue treatment. In conclusion, we show that amygdalin analogue reduces the proliferative capacity of psoriasis‐like stimulated keratinocytes and their inflammatory response in vivo and in vitro. These results suggest that topical application of amygdalin analogues may represent a safe and effective treatment for psoriasis. John Wiley and Sons Inc. 2021-05-28 2021-11 /pmc/articles/PMC8597152/ /pubmed/33998705 http://dx.doi.org/10.1111/exd.14390 Text en © 2021 The Authors. Experimental Dermatology published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Regular Articles Gago‐López, Nuria Lagunas Arnal, Carmen Perez, Juan J. Wagner, Erwin F. Topical application of an amygdalin analogue reduces inflammation and keratinocyte proliferation in a psoriasis mouse model |
title | Topical application of an amygdalin analogue reduces inflammation and keratinocyte proliferation in a psoriasis mouse model |
title_full | Topical application of an amygdalin analogue reduces inflammation and keratinocyte proliferation in a psoriasis mouse model |
title_fullStr | Topical application of an amygdalin analogue reduces inflammation and keratinocyte proliferation in a psoriasis mouse model |
title_full_unstemmed | Topical application of an amygdalin analogue reduces inflammation and keratinocyte proliferation in a psoriasis mouse model |
title_short | Topical application of an amygdalin analogue reduces inflammation and keratinocyte proliferation in a psoriasis mouse model |
title_sort | topical application of an amygdalin analogue reduces inflammation and keratinocyte proliferation in a psoriasis mouse model |
topic | Regular Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8597152/ https://www.ncbi.nlm.nih.gov/pubmed/33998705 http://dx.doi.org/10.1111/exd.14390 |
work_keys_str_mv | AT gagolopeznuria topicalapplicationofanamygdalinanaloguereducesinflammationandkeratinocyteproliferationinapsoriasismousemodel AT lagunasarnalcarmen topicalapplicationofanamygdalinanaloguereducesinflammationandkeratinocyteproliferationinapsoriasismousemodel AT perezjuanj topicalapplicationofanamygdalinanaloguereducesinflammationandkeratinocyteproliferationinapsoriasismousemodel AT wagnererwinf topicalapplicationofanamygdalinanaloguereducesinflammationandkeratinocyteproliferationinapsoriasismousemodel |